TY - JOUR
T1 - Deceptive morphologic and epigenetic heterogeneity in diffuse intrinsic pontine glioma
AU - Bugiani, Marianna
AU - Veldhuijzen van Zanten, Sophie
AU - Caretti, Viola
AU - Schellen, Pepijn
AU - Aronica, Eleanora
AU - Noske, David P.
AU - Vandertop, William P.
AU - Kaspers, Gertjan J.L.
AU - van Vuurden, Dannis G.
AU - Wesseling, Pieter
AU - Hulleman, Esther
N1 - Publisher Copyright:
© Bugiani et al.
PY - 2017/7/31
Y1 - 2017/7/31
N2 - Historically, the diagnosis of diffuse intrinsic pontine glioma (DIPG) was based on typical imaging findings and clinical characteristics instead of pathology. However, the discovery of mutations in histone H3 variants, and the availability of tumor material for molecular analysis, has led to a paradigm shift in DIPG research and clinical practice. Using data from whole-brain autopsies in a series of nine DIPG patients with known histone mutational status, we here aim to review histopathological characteristics with special focus on intratumoral heterogeneity (ITH) and histone 3 K27 trimethylation (H3 K27me3). All DIPGs showed marked histologic ITH, with 56% even showing focal areas resembling a WHO grade I phenotype. As expected, H3 K27me3 immunoreactivity was lost in the tumors that were H3 K27M-mutated (seven patients; 67% H3.3, 11% H3.1). Strikingly, the H3K27 wildtype tumors (two patients; 22%) also contained H3 K27me3-immunonegative areas. Our study underscores the importance of the choice of the biopsy site, as ITH in DIPGs could theoretically lead to erroneous histological diagnoses with small biopsies. New in this respect is our finding that a substantial number of otherwise typical DIPGs has areas resembling WHO grade I tumors (esp. pilocytic astrocytoma, subependymoma). Furthermore, our study shows that negative H3 K27me3 immunohistochemistry in a DIPG does not imply a H3 K27-mutant tumor.
AB - Historically, the diagnosis of diffuse intrinsic pontine glioma (DIPG) was based on typical imaging findings and clinical characteristics instead of pathology. However, the discovery of mutations in histone H3 variants, and the availability of tumor material for molecular analysis, has led to a paradigm shift in DIPG research and clinical practice. Using data from whole-brain autopsies in a series of nine DIPG patients with known histone mutational status, we here aim to review histopathological characteristics with special focus on intratumoral heterogeneity (ITH) and histone 3 K27 trimethylation (H3 K27me3). All DIPGs showed marked histologic ITH, with 56% even showing focal areas resembling a WHO grade I phenotype. As expected, H3 K27me3 immunoreactivity was lost in the tumors that were H3 K27M-mutated (seven patients; 67% H3.3, 11% H3.1). Strikingly, the H3K27 wildtype tumors (two patients; 22%) also contained H3 K27me3-immunonegative areas. Our study underscores the importance of the choice of the biopsy site, as ITH in DIPGs could theoretically lead to erroneous histological diagnoses with small biopsies. New in this respect is our finding that a substantial number of otherwise typical DIPGs has areas resembling WHO grade I tumors (esp. pilocytic astrocytoma, subependymoma). Furthermore, our study shows that negative H3 K27me3 immunohistochemistry in a DIPG does not imply a H3 K27-mutant tumor.
KW - histone 3
KW - intratumoral heterogeneity
KW - H3K27M
KW - trimethylation
KW - diffuse intrinsic pontine glioma
UR - http://www.scopus.com/inward/record.url?scp=85030462114&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.19726
DO - 10.18632/oncotarget.19726
M3 - Article
SN - 1949-2553
VL - 8
SP - 60447
EP - 60452
JO - Oncotarget
JF - Oncotarget
IS - 36
ER -